ANZCTR search results

This study will test whether a conservative treatment called full coronal pulpotomy can successfully save painful, deeply decayed adult teeth, even when some bleeding from the nerve tissue is deliberately allowed to continue before sealing the tooth. In this procedure, the dentist removes the inflamed nerve tissue from the crown of the tooth, places a modern bioactive cement over the remaining healthy pulp, and restores the tooth with a permanent filling, then reviews patients at 6 and 12 months to check pain levels, tooth function, and X-ray healing. The purpose is to see if this approach provides tooth survival and symptom relief that are not worse than those reported for conventional vital pulp therapy and standard root canal treatment, within a preplanned 10% margin. The study hypothesis is that allowing intentional uncontrolled bleeding (intentional uncontrolled haemostasis) during full coronal pulpotomy in these teeth will not lead to inferior 6 months or 12-month clinical and radiographic outcomes compared with published results for conventional vital pulp therapy and nonsurgical root canal treatment.

Gout is a painful form of arthritis caused by urate crystal deposition and is common in people with kidney failure receiving haemodialysis. Allopurinol is routinely prescribed to lower urate levels and prevent flares. However, haemodialysis itself removes urate, raising the possibility that some patients may no longer require allopurinol.. This pilot study will evaluate whether gradually stopping allopurinol is safe, effective, and feasible in haemodialysis patients with well-controlled gout. Participants will undergo stepwise dose reduction with regular blood tests and receive medication to prevent gout flares during the process. If a flare occurs, dose reduction will be stopped and usual treatment resumed. The study aims to reduce medication burden in this population and inform the design of a larger clinical trial and future clinical guidelines.

The PROTECT-PD Study is a randomised, double-blind, placebo-controlled study designed to assess the efficacy, safety and tolerability of Probucol (Lorelco™) in individuals with early to moderate Parkinson’s disease (PD). The trial will investigate whether Probucol can slow disease progression while maintaining an acceptable safety profile in approximately 140 participants. If you are eligible and choose to take part, you will be randomly assigned to receive either Probucol (Lorelco™) or a placebo (an inactive capsule). You will take two capsules each day, one in the morning and one at night. Your participation will last up to 82 weeks (about 19 months), including up to 8 weeks of screening, 78 weeks of treatment, and a 4-week follow-up after treatment ends.

The SIC PIN trial aims to evaluate the use of the Sirius Pintuition marker clip for non-palpable breast lesions in breast cancer diagnosis and surgery. Who is it for? You may be eligible for this trial if you are an adult female, non-lactating and have a impalpable breast lesion. Study details Participants will have the marker clips inserted by subspecialist breast Radiologists adjacent to non-palpable breast tumours. They will then go on to have surgical excision of these tumours. It is hoped that findings from this study will help inform researchers as to the utility and feasibility of the Sirius Pintuition marker clip in breast cancer diagnosis and surgery.

The present study aim is to evaluate the tolerability and feasibility of repeat LIFU treatments in participants with AD using a bespoke low frequency transcranial LIFU investigational device termed Ceretas Device. To evaluate the efficacy of the Ceretas device on the overall neuropsychiatric symptom burden in probable Alzheimer patients.

The EVADE-1 study aims to assess whether a new cancer treatment, evexomostat, shows signs of anti-cancer activity in patients with advanced prostate cancer that has spread to other tissues, and to better understand the safety and tolerability of this treatment in patients with advanced prostate cancer. Who is it for? You may be eligible for this study if you are aged 18 years or older, you have been diagnosed with metastatic castration-resistant prostate cancer and your cancer deposits/tumours also show low uptake on PSMA PET scans and/or increased uptake on FDG PET scans. You may need to ask your doctor to confirm whether your cancer meets these requirements. Study details All participants who choose to enrol in this study will be asked to attend the Princess Alexandra Hospital, Brisbane once per fortnight to receive an injection under the skin of evexomostat. If participants don't experience any severe side effects while receiving evexomostat, they will be able to continue attending fortnightly for up to 24 weeks (12 doses). Throughout the study, all participants will be asked to undergo additional PET/CT scans (4 in total), blood tests and clinical assessments to monitor their safety and any response to the treatment. It is hoped this research will determine whether regular doses of evexomostat are safe and tolerated by patients with advanced prostate cancer and to determine the effect of evexomostat on cancer activity. If the study finds that this treatment is safe and has an anti-cancer effect, a larger study to assess the treatment in a greater number of patients with advanced prostate cancer may be undertaken.

This study is testing a new online parenting program called ParentWorks-Unplugged, designed to help parents of preschool-aged children (3–6 years) build healthier technology habits at home and reduce the impact of screens on family life. Families will be randomly assigned to either complete the program straight away or after a short waiting period, allowing researchers to compare outcomes between groups. The study aims to examine whether the program is effective and helpful for parents. We expect that parents who complete the program will report less distraction from devices, reduced interference from technology in family interactions, and healthier technology use for both themselves and their child. We also expect improvements in children’s behaviour and emotional wellbeing, as well as stronger parent–child relationships and overall family functioning.

The SPRAINS (Sports-Related Adolescent Ankle Ligament INjury Surveillance) study is a 5-year prospective cohort study investigating ankle ligament sprains and chronic ankle instability in adolescent athletes at the Maribyrnong Sports Academy, Victoria, Australia. The study aims to determine the prevalence, risk factors, and outcomes associated with ankle ligament sprains in youth sport. Participants will complete annual questionnaires, clinical ankle assessments, and biomechanical testing using VALD ForceDecks. Athletes who sustain an ankle ligament sprain during the study period will complete additional post-injury assessments, including the Ankle-GO assessment tool. Findings from the study aim to improve understanding of ankle injury risk, recovery, and prevention strategies in adolescent athletes.

This study is investigating whether antibiotics that are usually given through a vein can instead be given under the skin (subcutaneously) in children. Giving antibiotics under the skin (subcutaneously) may reduce the need for intravenous lines, reduce complications, and improve comfort. Participants will receive their prescribed antibiotic through both methods in a randomised order. Blood samples will be collected to assess antibiotic blood levels in the body with each method. The study will also assess safety, pain and acceptability of each method.

The aim of this project is to develop, implement, and evaluate a consumer co-designed physical activity promotion program for community-dwelling individuals with moderate-to-profound disability. Through an extensive program of consumer engagement and stakeholder consultation, we will modify our efficacious best practice PA promotion model for people with disability - the Adapted Physical Activity Program (APAP) so it can be applied to support individuals with moderate-to-profound disabilities (APAP-OMNI). For implementation, we will co-design a workforce capacity and capability building training package to enable allied health professionals to deliver APAP-OMNI at scale in their own communities. We will evaluate the impact of the program in an Type 1 hybrid effectiveness-implementation cluster randomised trial and develop training resources to facilitate dissemination of the program to other communities. APAP-OMNI will improve access to safe and effective PA promotion services for people with disabilities who are currently under-served.